A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR) (DeFineDR)
A Clinical Trial Collecting Data From Routine Ophthalmological Examinations of Patients Who Were Randomized to Either Finerenone or Placebo in the Two Bayer-sponsored Phase 3 Clinical Trials FIDELIO-DKD and FIGARO-DKD to Investigate the Effect of Finerenone on Delaying the Progression of Diabetic Retinopathy
Sponsor: Bayer
A NA clinical study on Diabetic Retinopathy, this trial is completed. The trial is conducted by Bayer and has accumulated 7 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Dec 2022 — Jul 2024 [monthly]
Completed NA
-
Jul 2022 — Dec 2022 [monthly]
Completed NA
-
Sep 2021 — Jul 2022 [monthly]
Completed NA
Status: Recruiting → Completed
▶ Show 2 earlier versions
-
Jun 2021 — Sep 2021 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Apr 2021 — Jun 2021 [monthly]
Not Yet Recruiting NA
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .